Sun Pharmaceutical Industries Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

?ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to severe plaque psoriasis,? said Kirti Ganorkar, Managing Director, Sun Pharma. ?We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.?

ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term.

Powered by Capital Market - Live News

Sun Pharmaceutical Industries Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1744.2, up 0.7% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.28% on the day, quoting at 25949.3. The Sensex is at 84711.84, up 0.29%. Sun Pharmaceutical Industries Ltd has risen around 5.43% in last one month.

Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 3.33% in last one month and is currently quoting at 22593.4, up 0.8% on the day. The volume in the stock stood at 8.35 lakh shares today, compared to the daily average of 17.57 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 1748.4, up 0.53% on the day. Sun Pharmaceutical Industries Ltd is down 1.36% in last one year as compared to a 10.27% spurt in NIFTY and a 4.7% spurt in the Nifty Pharma index.

The PE of the stock is 88.9 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Formulation sales in India were Rs 4,734.8 crore, registering a growth of 11%. India Formulation sales accounted for 32.9% of total consolidated sales for the quarter.

Formulation sales in the US were $496 million registering a decline of 4.1%. The decline in generics business was offset by growth in Innovative Medicines. US sales accounted for approximately 30.1% of total consolidated sales.

Emerging Markets formulations sales were $325 million for Q2FY26, up by 10.9% and accounted for 19.7% of total consolidated sales.

Formulation sales in Rest of World (RoW) markets were US$ 234 million for Q2FY26, up by 17.7% and accounted for 14.2% of total consolidated sales for the quarter.

Global Innovative Medicines sales were US$ 333 million for Q2FY26, up 16.4% over Q2 last year and accounted for 20.2% of total consolidated sales for the quarter. During the quarter, Leqselvi was launched in the US for the treatment of severe alopecia areata and has received encouraging response from the prescribers and patients.

For Q2FY26, external sales of API were Rs 429.9 crore, down by 19.5%.

EBITDA for the period under review was Rs 4.527.1 crore, up 14.9% YoY. EBITDA margin for the September?25 quarter was 31.3%.

Total R&D expenditure for Q2 FY26 was Rs 782.65 crore, down 1.29% YoY.

Kirti Ganorkar, managing director of the company, said: ?India, Emerging Markets and Rest of World led our growth for the period. US sales of Innovative Medicines have surpassed Generics for the first time during the quarter. We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability.?

Sun Pharmaceutical Industries is the world?s leading specialty generics company with a presence in innovative medicines, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as global emerging markets.

The scrip fell 0.20% to currently trade at Rs 1689.40 on the BSE.

Powered by Capital Market - Live News

Net profit of Sun Pharmaceutical Industries rose 2.56% to Rs 3117.95 crore in the quarter ended September 2025 as against Rs 3040.16 crore during the previous quarter ended September 2024. Sales rose 8.60% to Rs 14405.22 crore in the quarter ended September 2025 as against Rs 13264.22 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News